Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalisation in EMPA-REG OUTCOME

Gary Solomons¹, Silvio E. Inzucchi², Christoph Wanner³, David Fitchett⁴, Bernard Zinman⁵, Stefan D. Anker⁶, Michaela Mattheus⁷, Ola Vedin⁸, Stefan Hantel⁹, Søren S. Lund¹⁰

1 Boehringer Ingelheim Ltd, Bracknell, UK
2 Section of Endocrinology, Yale University School of Medicine, New Haven, CT, USA
3 Würzburg University Clinic, Würzburg, Germany
4 St. Michael’s Hospital, Division of Cardiology, University of Toronto, ON, Canada
5 Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
6 Charité University, Berlin, Germany
7 Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
8 Boehringer Ingelheim AB, Stockholm, Sweden
9 Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
10 Boehringer Ingelheim International GmbH, Ingelheim, Germany